The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Hutchison Medipharma Limited is conducting a study to assess the Safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523, a syk inhibitor, in adult patients with immune thrombocytopenia. This is a randomized, double blinded, placebo controlled phase Ib study where participants can expect to receive the sky inhibitor for up to eight weeks. Participants must be refractory to other therapies and be between ages 18 years – 75 years of age, and have either persistent or chronic ITP.



back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo